BTK and autoimmune thrombocytopenic purpura: Once the results of the currently ongoing trials are available [62], a comparison with those obtained by reversible BTK inhibitors will allow researchers to assess whether or not second-generation irreversible inhibitors are superior for targeting BTK in ITP.